Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27708260 | 0.79 | MAP2K1 (0.71) | MAP2K1KDRADORA2ACCNE1CDK2 | |
| SCHEMBL30333809 | 0.77 | PCSK9 (0.57) | MAP2K1CCND3CDK6NPC1RAB9A | |
| SCHEMBL7978672 | 0.76 | KDM4E (0.55) | MAP2K1NPC1RAB9AKDRADORA2A | |
| SCHEMBL878719 | 0.76 | MAP2K1 (0.61) | MAP2K1KDRADORA2ACCNE1CDK2 | |
| SCHEMBL7981073 | 0.74 | MAP2K1 (0.60) | MAP2K1NPC1RAB9AKDRADORA2A | |
| SCHEMBL27654304 | 0.74 | RAB9A (0.60) | MAP2K1CCND3CDK6NPC1RAB9A | |
| SCHEMBL250171 | 0.74 | CCND3 (0.70) | MAP2K1CCND3CDK6NPC1RAB9A | |
| SCHEMBL31222717 | 0.74 | PCSK9 (0.57) | CCND3CDK6NPC1RAB9APCSK9 | |
| SCHEMBL985214 | 0.73 | MAP2K1 (0.71) | MAP2K1ADORA2ACCNE1CDK2GPR84 | |
| SCHEMBL29468201 | 0.73 | MAP2K1 (0.71) | MAP2K1ADORA2ACCNE1CDK2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417399-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS AND THERAPEUTIC USES THEREOF | GALILEO BIOSYSTEMS INC (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2023064486-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS AND THERAPEUTIC USES THEREOF | GALILEO BIOSYSTEMS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417399-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS AND THERAPEUTIC USES THEREOF | AHR, ARNT, NR1H2 | MAP2K1 3663/4885CCND3 4004/4885CDK6 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.